January 28 - Cases in Precision Oncology: Highlights from the 2024 ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board Case Series
(4)
Image For Activity Cover
Availability
No future session
Expires on Feb 28, 2025
Cost
$0.00
Credit Offered
1 CME (AMA) Credit
1 CME (Other) Credit


Cases in Precision Oncology: Highlights from the 2024 ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board Case Series

Tuesday, January 28th, 2025
11:00am-12:00pm ET
www.acmgeducation.net

Course Description
Cases in Precision Oncology: Highlights from the 2024 ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board Case Series

This CME Case Series reflects the work of molecular tumor boards by featuring an interdisciplinary discussion of cases that are subject to comprehensive molecular characterization using a variety of advanced technologies. . The molecular characterization of tumor samples ranges from methods on the genomic level to recent advances in proteomics. The field is advancing rapidly, and more and more approaches will translate from basic research to clinical care. In this session, we will summarize the variety of methods described in previous virtual molecular tumor boards and highlight the most interesting cases from 2024. In addition, we will give an outlook on topics to come in 2025.

Target Audience
All medical and healthcare professionals and researchers interested in understanding cancer genomic testing and somatic and germline variant interpretation methods. This series is presented as a collaboration between ClinGen Somatic, VICC, and ACMG consortia. 

Agenda
Presentations followed by live Q&A.  

Learning Objectives
At the conclusion of this session, participants should be able to:

1.    Name three different types of molecular characterization methods.
2.    Explain how different types of results can be integrated to benefit a cancer patient.
3.    Describe one major challenge in precision oncology.

no image

Manuela Benary, PhD

Bioinformatician

Charité – Universitätsmedizin Berlin, Berlin, Germany

 

no image

 

Beth Pitel, MS

Clinical Variant Scientist – Oncology

Assistant Professor of Laboratory Medicine and Pathology

Mayo Clinic

Jason Saliba, PhD

Senior Scientist at Washington University School of Medicine in St. Louis

 



Planning Committee:
Beth Pitel, MS, CG(ASCP)
Gordana Raca, MD, PhD, FACMG
Manuela Benary, PhD
Jason Saliba, PhD
Jane Radford, MHA, CHCP
Claudia Barnett

CME AMA PRA Category 1 CreditTM, & CME Other

 Accreditation 

The American College of Medical Genetics and Genomics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Credit Designation 

The American College of Medical Genetics and Genomics designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Claiming your Educational Credits 

Complete the activity and carefully complete the evaluation form. The deadline to claim educational credits is within 30 days from the date of the activity. Educational credit requests after this date will not be accepted. 

Learner Data Consent 

ACMG Education reports learner data to respective agency boards and you will be asked for consent during the evaluation process. Your compliance with deadlines and completing evaluations are part of the process in meeting learner needs and ACMG’s education mission.  

 Technical Support: 

You can reach us by email at education@acmg.net or call 301-718-9603. 

Support Center Hours: Monday – Friday, 9:00 AM – 5:00 PM Eastern Time. 

Accredited Continuing Education Financial Disclosure

The American College of Medical Genetics and Genomics (ACMG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Accredited Continuing Education (ACE) for physicians. ACMG is an organization committed to improvement of patient care and general health by the incorporation of genetics and genomics into clinical practice.

 

ACMG has implemented the following procedures to ensure the independence of ACE activities from commercial influence/promotional bias, the Accreditation Council for Continuing Medical Education (ACCME) requires that providers (ACMG) must be able to demonstrate that: 1) everyone in a position to control the content of an ACE activity has disclosed all financial relationships that they have had in the past 24 months with ineligible* companies; 2) ACMG has implemented a mechanism to mitigate relevant financial relationships; and 3) all relevant financial relationships with ineligible companies are disclosed to the learners before the beginning of the educational activity. The learners must also be informed if no relevant financial relationships exist.
*Ineligible companies are defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

 

ACMG Education Policies

Please review the policies below regarding the ACMG Education program

 

All of the relevant financial relationships listed for these individuals have been mitigated.

 

NAME

ROLE

RELATIONSHIP/ COMPANY

 

Planning Member

Presenter Panelist Moderator

Peer Reviewer

 

Beth Pitel, MS, CG(ASCP)

 ● 

 

 

Advisory Board: Qiagen, LLC

Claudia Barnett

 

 

Nothing to Disclose.

Gordana Raca, MD, PhD, FACMG

 

Nothing to Disclose.

Jane Radford, MHA, CHCP

 

 

Nothing to Disclose.

Jason Saliba, PhD

  

 

 

Nothing to Disclose.

Manuela Benary, PhD

 ● 

 

Nothing to Disclose.

 

© 2025 American College of Medical Genetics and Genomics. All rights reserved.

Powered By